Radboud University Medical Center

🇳🇱Netherlands

Country: 🇳🇱Netherlands

Ownership: Private

Established: 1951-01-01

Employees: -

Market Cap: -

Website: http://www.radboudumc.nl

Clinical Trials

the Influence of Remote Ischemic Preconditioning on Inflammation During Human Endotoxemia

Early Phase 1

Completed

Conditions: Autoimmune Diseases
Infection

Interventions: Other: Single-dose Remote Ischemic Preconditioning
Other: Multiple-dose Remote Ischemic Preconditioning
Biological: LPS infusion

First Posted Date: 2015-11-11

Last Posted Date: 2016-04-04

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 30

Registration Number: NCT02602977

Locations: 🇳🇱
Radboud University Medical Centre, Intensive Care, Nijmegen, Netherlands

myDC/pDC in Stage III Melanoma Patients

Phase 1

Completed

Conditions: Melanoma

First Posted Date: 2015-10-12

Last Posted Date: 2021-09-20

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 30

Registration Number: NCT02574377

Locations: 🇳🇱
Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands

Bioequivalence Study of CRushed TriUMeq With or Without Drip Feed Compared to the Whole Tablet

Phase 1

Completed

Conditions: HIV

Interventions: Drug: Triumeq crushed + breakfast
Drug: Triumeq
Drug: Triumeq crushed + drip feed

First Posted Date: 2015-10-06

Last Posted Date: 2020-12-07

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 22

Registration Number: NCT02569346

Locations: 🇳🇱
CRCN, Radboud University Medical Center, Nijmegen, Netherlands

Pharmacokinetics of Atazanavir /Dolutegravir/Lamivudine Regimen as Maintenance Regimen

Phase 2

Terminated

Conditions: HIV-1 Infection

Interventions: Drug: Atazanavir
Drug: Dolutegravir
Drug: Lamivudine

First Posted Date: 2015-10-02

Last Posted Date: 2020-12-07

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 9

Registration Number: NCT02566707

Locations: 🇳🇱
St. Elisabeth, Tilburg, Netherlands
🇳🇱
Rijstate, Arnhem, Netherlands
🇳🇱
Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands

and more 1 locations

A Drug-drug Interaction Study Between Daclatasvir and Metformin

Phase 1

Completed

Conditions: Hepatitis C
Diabetes Mellitus
Insulin Resistance

Interventions: Drug: Daclatasvir
Drug: Metformin

First Posted Date: 2015-10-01

Last Posted Date: 2020-12-07

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 20

Registration Number: NCT02565862

Locations: 🇳🇱
CRCN, Radboud University Medical Center, Nijmegen, Netherlands

A Drug-drug Interaction Study Between Daclatasvir and Atazanavir/Ritonavir or Atazanavir/Cobicistat

Phase 1

Completed

Conditions: Hepatitis C
HIV

Interventions: Drug: Daclatasvir
Drug: Atazanavir
Drug: Cobicistat
Drug: Ritonavir

First Posted Date: 2015-10-01

Last Posted Date: 2020-12-07

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 16

Registration Number: NCT02565888

Locations: 🇳🇱
CRCN, Radboud University Medical Center, Nijmegen, Netherlands

Exacerbation Self-management in COPD: The ACCESS Study

Not Applicable

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Interventions: Device: ACCESS

First Posted Date: 2015-09-17

Last Posted Date: 2017-08-30

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 87

Registration Number: NCT02553096

Locations: 🇳🇱
Radboud University Medical Centre, Department of Primary and Community Care, Nijmegen, Netherlands

Visualizing Beta Cells After Bariatric Surgery

Recruiting

Conditions: Type 2 Diabetes Mellitus

Interventions: Radiation: 68Ga-exendin PET/CT

First Posted Date: 2015-09-04

Last Posted Date: 2023-12-08

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 24

Registration Number: NCT02542059

Locations: 🇳🇱
RadboudUMC, Nijmegen, Gelderland, Netherlands
🇳🇱
Rijnstate Hospital, Arnhem, Gelderland, Netherlands

Effect of Gelofusine on GLP1-receptor Imaging

Phase 1

Completed

Conditions: Diabetes Mellitus, Non-Insulin-Dependent
Diabetes Mellitus

Interventions: Radiation: 111In-exendin 4 SPECT/CT
Drug: Gelofusine
Drug: Placebo

First Posted Date: 2015-09-04

Last Posted Date: 2017-05-31

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 12

Registration Number: NCT02541734

Adipose Tissue Imaging in Type 2 Diabetes

Not Applicable

Completed

Conditions: Diabetes Mellitus Type 2

Interventions: Radiation: 18F-FDG PET/CT
Device: hypoglycemic clamp
Device: euglycemic clamp

First Posted Date: 2015-08-19

Last Posted Date: 2017-05-31

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 15

Registration Number: NCT02528695

Locations: 🇳🇱
RadboudUMC, Nijmegen, Gelderland, Netherlands

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy